Mogroside V: A Review of Its Structure, Synthesis, Pharmacokinetics, and Toxicity

Mogroside V (MOG‐V), a natural triterpene glycoside predominantly derived from the fruit pulp of Siraitia grosvenorii , is widely recognized as a high‐intensity non‐caloric sweetener. In recent years, it has attracted considerable research interest due to its broad pharmacological activities, including anti‐inflammatory, antioxidant, anticancer, and neuroprotective effects. Notably, MOG‐V exhibits a remarkable capacity to scavenge intracellular reactive oxygen species (ROS), thereby supporting mitochondrial function and promoting cellular homeostasis. It has also shown promising efficacy in alleviating pneumonia. Mechanistic studies indicate that MOG‐V modulates glucose and lipid metabolism through activation of the AMPK signaling pathway. Furthermore, it confers neuroprotective benefits in models of Parkinson's disease via regulation of critical metabolic pathways. Despite these advances, a comprehensive and critical outlook on the synthesis, pharmacological mechanisms, and therapeutic applications of MOG‐V remains lacking. Based on the current research status and existing limitations, this review provides a comprehensive analysis of MOG‐V, including its structural characteristics, novel synthetic approaches, and pharmacological investigations. Furthermore, it critically evaluates the therapeutic potential of MOG‐V and identifies promising directions for future research. This study systematically consolidates and assesses the available knowledge of MOG‐V, with the aim of clarifying its mechanistic foundations and proposing novel insights for subsequent studies.